ARNI Recent News Arno Therapeutics names Lawrence
Post# of 9
Posted On: 03/02/2014 5:28:13 PM
ARNI Recent News
Arno Therapeutics names Lawrence A Kenyon as CFO M2 - Fri Feb 28, 3:27AM CST
Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer GlobeNewswire - Thu Feb 27, 9:00AM CST
Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors GlobeNewswire - Tue Jan 21, 11:06AM CST
Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders GlobeNewswire - Mon Jan 13, 7:15AM CST
Arno Therapeutics to Present at Biotech Showcase 2014 GlobeNewswire - Thu Jan 09, 7:30AM CST
Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone GlobeNewswire - Tue Jan 07, 7:15AM CST
Arno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013 GlobeNewswire - Sat Dec 14, 7:30AM CST
Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split GlobeNewswire - Wed Oct 30, 7:00AM CDT
Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer GlobeNewswire - Tue Oct 29, 4:00PM CDT
Arno Therapeutics Inc submits IMPD to ANSM for planned Phase I trial of onapristone in PR positive tumors trial M2 - Tue Sep 10, 8:59AM CDT
Arno Therapeutics names Lawrence A Kenyon as CFO M2 - Fri Feb 28, 3:27AM CST
Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer GlobeNewswire - Thu Feb 27, 9:00AM CST
Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors GlobeNewswire - Tue Jan 21, 11:06AM CST
Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders GlobeNewswire - Mon Jan 13, 7:15AM CST
Arno Therapeutics to Present at Biotech Showcase 2014 GlobeNewswire - Thu Jan 09, 7:30AM CST
Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone GlobeNewswire - Tue Jan 07, 7:15AM CST
Arno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013 GlobeNewswire - Sat Dec 14, 7:30AM CST
Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split GlobeNewswire - Wed Oct 30, 7:00AM CDT
Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer GlobeNewswire - Tue Oct 29, 4:00PM CDT
Arno Therapeutics Inc submits IMPD to ANSM for planned Phase I trial of onapristone in PR positive tumors trial M2 - Tue Sep 10, 8:59AM CDT
(0)
(0)Arno Therapeutics, Inc. (ARNI) Stock Research Links
Scroll down for more posts ▼